CCDC167 is encoded by the ccdc167 gene (Entrez Gene ID: 100125155) in Xenopus tropicalis. Key characteristics include:
The protein’s coiled-coil domain suggests roles in structural organization or scaffold formation, potentially influencing mitotic processes or signaling pathways .
Recombinant CCDC167 is typically expressed in E. coli with an N-terminal His-tag for purification. Key production parameters include:
The recombinant protein’s stability and solubility are optimized for biochemical assays, including ELISA, Western blot, or interaction studies .
CCDC167 interacts with diverse cellular components and pathways, as inferred from functional databases:
| Protein | Function |
|---|---|
| ARFGEF3 | Regulates insulin granule biogenesis in pancreatic β-cells |
| CHMP7 | Involved in nuclear envelope sealing during mitosis |
| SAC3D1 | Promotes centrosome duplication and mitotic progression |
| LRRTM4 | Excitatory synaptogenesis in neuronal systems |
These interactions suggest CCDC167 may regulate organelle dynamics, cell division, or synaptic plasticity.
Cell Cycle Regulation: APC-CDH1 complex-mediated mitotic progression.
Immune Response: Interferon (IFN)-α/β signaling and MHC class I antigen presentation.
Ubiquitination: Metabolism of ubiquitin-like modifiers (e.g., SUMO).
Recombinant CCDC167 is utilized in studies probing its role in disease and basic biology:
| Parameter | Detail |
|---|---|
| Product | Xenopus CCDC167 ELISA kit (50 µg vial) |
| Sensitivity | Optimized for detecting endogenous or recombinant CCDC167 |
| Applications | Quantifying protein levels in lysates or conditioned media |
While human CCDC167 is implicated in breast cancer progression, the recombinant Xenopus protein may serve as a model for studying:
Proliferation: Knockdown reduces colony formation in breast cancer cell lines (e.g., MCF-7).
Drug Response: Chemotherapeutic agents (e.g., doxorubicin) downregulate CCDC167 expression.
KEGG: xtr:100125155
UniGene: Str.52526